SRX price drive would present as market over-reaction.
In early March, SRX in their clinical briefing (according to UBS) presented differential commerical outcomes of various trials.
SRX detailed the designs and potential commercial outcomes of each of its key HCC (primary liver) & mCRC (metastatic colorectal) clinical studies. Under a scenario where no studies are successful, SRX's salvage business still has significant growth opportunities including indication expansion (e.g. HCC in US) & geographical expansion incl. into China and Japan (SRX estimates a global salvage opportunity of 329k patients / year).
UBS valuation (DFC) approach does include trial outcomes. UBS said that, "should the trials fail to meet endpoints, at current trading levels we believe the downside risk to the share price is modest"
SRX price drive would present as market over-reaction. In early...
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 6422505 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1240300 | 15 |
View Market Depth
| Last trade - 10.08am 31/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |
Day chart unavailable